Physician profile
Stacey E Bacon
NPI 1003066085
$531.64
in general payments reported to CMS, 2019-2025
11 companies · $78.00 in 2025
The $78.00 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.74 · 2023: $18.65 · 2024: $410 · 2025: $78.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.41 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $196.90 | 2024 | Austedo Xr, Uzedy |
| Abbvie INC. | $88.26 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $57.88 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $40.05 | 2024 | Aristada, Aristada Initio, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.53 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $30.11 | 2024 | Hetlioz, Fanapt |
| Allergan, INC. | $24.74 | 2021 | |
| Axsome Therapeutics, INC. | $18.29 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $16.45 | 2024 | Cobenfy |
| Neurocrine Biosciences, INC. | $14.80 | 2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $13.63 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.